Prescription Drug Price Transparency
Announcements

MDH shares recent information related to the Prescription Drug Price Transparency Act's implementation on this page. 

MDH invites your ideas or suggestions for prescription drugs on which to collect data. Visit Public Input for information on how to provide feedback.

Sign up for email updates to receive news and notifications.

April 2026 List of Drugs of Substantial Public Interest posted

April 13, 2026

MDH has posted the April 2026 List of Drugs of Substantial Public Interest. This list is based on the first group of drugs selected for negotiation under the Medicare Drug Price Negotiation Program, which was authorized as part of the Inflation Reduction Act of 2022. To view the list and accompanying methodology, visit Drugs of Substantial Public Interest Lists.

Manufacturers, pharmacies, wholesalers, and PBMs with a reporting obligation will be notified of the need to report no sooner than 30 days after this release and will have 60 days after the date of notification to report. Reporting guidance and supporting materials are available on Reporting Resources. 

Updated data

December 2, 2025

The Minnesota Department of Health (MDH) has released new data contained in online data dashboards and downloadable files for the Minnesota Prescription Drug Price Transparency initiative. Visit RxPT Data and Dashboards to access the interactive and downloadable files. 

Final reporting guidance released

November 10, 2025

MDH has released final Form and Manner for Prescription Drug Data Sets (PDF). 

Updates reflect statutory changes from the 2025 legislative session (Laws of Minnesota, 2025—1st special session, chapter 3, article 2, sections 6-14) and responses to comments received during the recent comment period. The updates include changes to align reporting elements, modified registration requirements, and a change to the reporting period on which to report data for drugs of substantial public interest.  

MDH has also released an updated RxPT: Frequently Asked Questions (PDF) document. 

MDH released 2025 Report to the Minnesota Legislature

November 4, 2025

MDH released the Minnesota Prescription Drug Transparency: 2025 Report to the Minnesota Legislature (PDF). It presents analysis of information reported to MDH through June 2024, provides a summary and timeline for the implementation of new work, and assesses the Act’s progress toward statutory goals.

Updated draft reporting guidance available for public comment

August 25, 2025

MDH has released updated Draft Form and Manner for Prescription Drug Data Sets (PDF) for public comment. Stakeholders may submit comment by emailing health.Rx@state.mn.us by 4:30 p.m. CT on Monday, September 8, 2025. 

Updates reflect statutory changes from the 2025 legislative session (Laws of Minnesota, 2025—1st Special Session, chapter 3, article 2, sections 6-14). They include changes to align reporting elements, modified registration requirements, and a change to the reporting period on which to report data for drugs of substantial public interest. 

Comment deadline: 

Monday, September 8, 2025, at 4:30 p.m. CT

Please email written comments to health.Rx@state.mn.us. 

Updated data

June 9, 2025

The Minnesota Department of Health (MDH) has released new data contained in online data dashboards and downloadable files for the Minnesota Prescription Drug Price Transparency initiative. Access the interactive dashboards and downloadable files on the RxPT Data and Dashboards webpage. 

Now open: Reporting on the newest list of Drugs of Substantial Public Interest

April 23, 2025

Reporting is now open in the Rx Data Portal for the most recent list of Drugs of Substantial Public Interest. Visit the Public Interest Drug Lists webpage for details. MDH sent notifications to entities registered in the Portal on 4/21/2025. Reports are due 60 days later, 6/20/2025. The date range for data this reporting period is 04/01/2024 through 3/31/2025.